Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Biofrontera ( (BFRI) ) is now available.
On March 9, 2026, Biofrontera Inc. announced positive Phase 2b trial results for its Ameluz® photodynamic therapy in moderate to severe acne vulgaris, showing greater reductions in inflammatory lesions and better mIGA scores than vehicle, particularly with a 3-hour incubation regimen. The data, including a 57.97% lesion reduction in the Ameluz arm versus 36.51% for vehicle and high patient satisfaction, support further development and could significantly broaden Ameluz’s indications, strengthening Biofrontera’s position in the large acne treatment market.
The therapy showed a favorable safety and tolerability profile, with mainly mild to moderate burning and pruritus and modest pain scores reported during treatment. Biofrontera plans to present the Phase 2b findings to the U.S. Food and Drug Administration in the third quarter of 2026 to discuss subsequent clinical steps, positioning the company to potentially offer an in-office alternative to long-term topical or systemic acne therapies amid rising concern over antibiotic resistance.
The most recent analyst rating on (BFRI) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
The score is held down primarily by weak financial performance—persistent operating losses, continued cash burn, and negative equity. Technicals are mixed and do not provide strong confirmation of a durable uptrend, while valuation is difficult to support given negative earnings and no dividend. Offsetting factors include earnings-call guidance targeting FY2026 cash-flow breakeven and margin improvement from acquiring U.S. rights, but near-term listing/compliance risk remains a notable headwind.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology, specializing in photodynamic therapy for skin conditions. The company commercializes the Ameluz® drug-device combination with RhodoLED® lamp systems for treating actinic keratosis and is conducting trials to expand use into non-melanoma skin cancers and moderate to severe acne.
Average Trading Volume: 475,133
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.01M
For detailed information about BFRI stock, go to TipRanks’ Stock Analysis page.